Literature DB >> 22330846

Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment.

Jean L Scholz1, Michael P Cancro.   

Abstract

Competition for limited, cell extrinsic survival factors is a general feature of peripheral selection checkpoints involved in B lymphocyte maturation and activation. Perhaps the best-characterized example involves BLyS (B lymphocyte stimulator), which modulates the size and composition of mature naïve B cell pools, but evidence for analogous competitive checkpoints is emerging for both germinal center B cells and plasma cells. Here we discuss how deliberate alteration of BLyS levels might be used to manipulate B cell repertoire selection in order to restore self-tolerance in autoimmunity, remodel the repertoire to accommodate neo-self antigens introduced through transplantation and gene therapy, or expand repertoire diversity to reveal novel, therapeutically useful specificities.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22330846      PMCID: PMC3677571          DOI: 10.1016/j.imlet.2012.01.014

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  134 in total

1.  The rise and fall of horror autotoxicus and forbidden clones.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Kidney Int       Date:  2010-09       Impact factor: 10.612

Review 2.  Control systems and decision making for antibody production.

Authors:  Christopher C Goodnow; Carola G Vinuesa; Katrina L Randall; Fabienne Mackay; Robert Brink
Journal:  Nat Immunol       Date:  2010-07-20       Impact factor: 25.606

3.  Lifetime of plasma cells in the bone marrow.

Authors:  R A Manz; A Thiel; A Radbruch
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

4.  Off-label use of rituximab in a multipayer insurance system.

Authors:  Eliezer M Van Allen; Todd Miyake; Nathan Gunn; Caroline M Behler; Jeff Kohlwes
Journal:  J Oncol Pract       Date:  2011-03       Impact factor: 3.840

5.  Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF.

Authors:  Ronald F Parsons; Ming Yu; Kumar Vivek; Ghazal Zekavat; Susan Y Rostami; Amin S Ziaie; Yanping Luo; Brigitte Koeberlein; Robert R Redfield; Christopher D Ward; Thi-Sau Migone; Michael P Cancro; Ali Naji; Hooman Noorchashm
Journal:  Transplantation       Date:  2012-04-15       Impact factor: 4.939

Review 6.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

Authors:  Petra Roll; Arumugam Palanichamy; Christian Kneitz; Thomas Dorner; Hans-Peter Tony
Journal:  Arthritis Rheum       Date:  2006-08

Review 8.  Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?

Authors:  M Sioud
Journal:  Scand J Immunol       Date:  2009-12       Impact factor: 3.487

9.  Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function.

Authors:  Kalpit A Vora; Li Chun Wang; Sambasiva P Rao; Zhong-Ying Liu; Gerard R Majeau; Anne H Cutler; Paula S Hochman; Martin L Scott; Susan L Kalled
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

10.  APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Authors:  Elodie Belnoue; Maria Pihlgren; Tracy L McGaha; Chantal Tougne; Anne-Françoise Rochat; Claudia Bossen; Pascal Schneider; Bertrand Huard; Paul-Henri Lambert; Claire-Anne Siegrist
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

View more
  8 in total

1.  Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis.

Authors:  Jun Zhang; Weici Zhang; Patrick S C Leung; Christopher L Bowlus; Sandeep Dhaliwal; Ross L Coppel; Aftab A Ansari; Guo-Xiang Yang; Jinjun Wang; Thomas P Kenny; Xiao-Song He; Ian R Mackay; M Eric Gershwin
Journal:  Hepatology       Date:  2014-09-29       Impact factor: 17.425

2.  Differences in mouse and human nonmemory B cell pools.

Authors:  Abigail Benitez; Abby J Weldon; Lynnette Tatosyan; Vani Velkuru; Steve Lee; Terry-Ann Milford; Olivia L Francis; Sheri Hsu; Kavoos Nazeri; Carlos M Casiano; Rebekah Schneider; Jennifer Gonzalez; Rui-Jun Su; Ineavely Baez; Keith Colburn; Ioana Moldovan; Kimberly J Payne
Journal:  J Immunol       Date:  2014-04-09       Impact factor: 5.422

Review 3.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 4.  The BAFFling effects of rituximab in lupus: danger ahead?

Authors:  Michael R Ehrenstein; Charlotte Wing
Journal:  Nat Rev Rheumatol       Date:  2016-02-18       Impact factor: 20.543

Review 5.  Chronic inflammation and aging: DNA damage tips the balance.

Authors:  Mary M Cavanagh; Cornelia M Weyand; Jörg J Goronzy
Journal:  Curr Opin Immunol       Date:  2012-05-05       Impact factor: 7.486

6.  Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B cell responses.

Authors:  Gregg J Silverman; Adam Pelzek
Journal:  J Rheumatol       Date:  2014-04-01       Impact factor: 4.666

7.  γδ T Cells Shape Preimmune Peripheral B Cell Populations.

Authors:  Yafei Huang; Andrew Getahun; Ryan A Heiser; Thiago O Detanico; Katja Aviszus; Greg A Kirchenbaum; Tamara L Casper; Chunjian Huang; M Kemal Aydintug; Simon R Carding; Koichi Ikuta; Hua Huang; Lawrence J Wysocki; John C Cambier; Rebecca L O'Brien; Willi K Born
Journal:  J Immunol       Date:  2015-11-18       Impact factor: 5.422

Review 8.  Molecular signature in HCV-positive lymphomas.

Authors:  Valli De Re; Laura Caggiari; Marica Garziera; Mariangela De Zorzi; Ombretta Repetto
Journal:  Clin Dev Immunol       Date:  2012-08-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.